- Developed nano material, the core material of OLED, with Korean technology and successfully implemented mass production system
- Goal to develop as the best supplier of experimental materials and advanced materials in Korea
Located in the Knowledge Industrial Complex of SongdoTechnopark, Incheon, Avention is successfully localizing cutting-edgeexperimental materials by developing and manufacturing reagents andnanomaterials for researchers. Avention has strengthened its position as a basematerial manufacturer, and successfully developed nanomaterials, an importantmaterial for OLED encapsulants with its own technology after two years ofeffort. It has now begun supplying them to large Korean companies after massproduction tests. This achievement of Avention opened the way for materialtechnology independence by replacing Japanese products that occupied more than90% of the Korean market with its products. And at the same time, Aventioncontributed to enhancing the competitiveness of finished products by stablysupplying the high-quality materials to Korean companies.
The amount of R&D investment and execution inKorea is about 90 trillion won, ranking fifth in the world, and the ratio ofresearchers per 1,000 people is also second highest in the world after Israel.“I felt bad that most of the reagents and basic experimental materials that arethe basis of all research activities in Korea with a substantial market sizewere imported from foreign countries,” said Han Kyung-sik, CEO of Avention. Hethen explained, “To secure sustainable competitiveness, I thought we had to benationally independent in basic materials, which is why I founded the company.”
The organization of Avention, which owns and operatesmore than 200,000 kinds of experimental materials, which is the largest inKorea, consists of Metals Division and Reagents Division. The Metals Divisionis in charge of developing and processing nano powders and CNTs, high-puritymetals and alloying materials, and the Reagents Division is in charge ofdeveloping and producing analytical reagents, synthetic reagents, plantextracts, and organic-inorganic compounds. CEO Han explained, "All ourproducts are manufactured and managed under high quality control, and we issuereports for all productions by order."
In its sixth year of establishment this year, Aventionis equipped with a corporate research institute and its own productioninfrastructure, providing one-stop service from customer requests to materialdevelopment, product production, and delivery. “The parts which researchers aremost concerned about are product quality and delivery delay,” said Han, whothen said, “Distrust in this part has evolved to having excessive trust towardsproducts made in Japan and Europe.” He added, “Our company has resolved this byproviding one-stop solution, and we are raising the trust by designated themanager in charge for each customer.”
In addition to the technological growth made byacquiring more than three related patents and certifications including INNOBIZ(technological innovative SME), Main Biz (management-innovative SME), andmaterials, parts and equipment specialist, Avention is establishing itself as aglobal company with global distribution network in the US and China branches.Along with this, Avention made a new division in the company called BioDivision early this year to expand the research area to include antibodies, proteins,and plant extracts. Based on expertise in technical support, it is respondingquickly and effectively to customer needs. In addition, by expanding thedistribution warehouse sized 2,000 pyeong within this year, it is preparing torespond to increasing demand with fast delivery.
Han said, “I want to contribute to the development ofbasic science in Korea by developing and distributing bio-reagents andnanomaterials necessary for R&D in the chemical, bio, and pharmaceuticalindustries with the corporate spirit of creating customer value throughinnovation.” He then added, “As the healthcare industry is attracting attentiondue to the emergence of new viruses, aging, and preventive medicine, we areplanning to expand our business area to a life science material company in thefuture.”